Study wrapper · #857

How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.

Levi J, Cross S, Ramesh N, et al. Obesity (Silver Spring, Md.). 2026.

Editor's note

A cost-plus pricing analysis projecting that generic semaglutide could reach $28-$140 per person-year for injectables once patents lapse in 2026, with access potentially opening in 162 countries. This is a market and access study, not a clinical one, so no efficacy question is at stake, but it is highly relevant to anyone tracking the peptide market's economics. The estimates rest on Indian API shipment data and modeling assumptions, and device costs and secondary patents are flagged as real limits on the rosy access picture.

Plain-language abstract

Researchers estimate that once semaglutide's patents expire in 2026, generic injectable versions could cost as little as $28 to $140 per person per year, potentially expanding access across most of the world.

Weak / none

A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.

Scandinavian journal of primary health caren=——2026

Mixed

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.

Annals of medicinen=——2026

Weak / none

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economicsn=——2026

All studies for Semaglutide →

Methodology

How we rate evidence

Our 4-tier evidence rating system, why study design and sample size matter, and how we handle conflicting results.

Read methodology →